Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

City Therapeutics, Inc., a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

EconoTimes is a global, independent publication that delivers comprehensive news, analysis, and insights on the economy, finance, and markets. Based in Korea, we offer a unique perspective on global ...

💊 Sanofi’s Qfitlia (fitusiran) has just received FDA approval - introducing the first siRNA therapy for haemophilia A & B. This innovative treatment helps prevent bleeds and brings real hope ...

The US Food and Drug Administration granted clearances for testing instruments, a blood clot drug companion diagnostic test, and infectious disease tests, among other devices.

Sanofi (SNY) stock slips as the company's asthma therapy amlitelimab fails in a Phase 2 trial, despite its plans to evaluate ...

Sanofi (NASDAQ:SNY) announced Tuesday that its TIDE-Asthma Phase 2 study for its T-cell-depleting monoclonal antibody amlitelimab didn’t reach the primary endpoint for the highest dose level but ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2025 on Thursday, May ...

This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...